CA_logo-blueCaring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

May 2010

 

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Telaprevir for previously treated chronic HCV infection. McHutchison JG, Manns MP, Muir AJ, et al. N Engl J Med. 2010 Apr 8;362(14):1292-303.

http://www.ncbi.nlm.nih.gov/pubmed/20375406

 

Peginterferon alpha-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study. Balart LA, Lisker-Melman M, Hamzeh FM, et al. Am J Gastroenterol. 2010 Apr 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20389293

 

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Feuerstadt P, Bunim AL, Garcia H, et al. Hepatology. 2010 Apr;51(4):1137-43.

 

Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. Bokharaei Salim F, Keyvani H, Amiri A, et al. World J Gastroenterol. 2010 Apr 28;16(16):2005-9.

http://www.ncbi.nlm.nih.gov/pubmed/20419838

 

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Martinot-Peignoux M, Stern C, Maylin S, et al. Hepatology. 2010 Apr;51(4):1122-6.

http://www.ncbi.nlm.nih.gov/pubmed/20069649

 

Extrahepatic manifestations associated with chronic hepatitis C infections in Poland.

Zarebska-Michaluk DA, Lebensztejn DM, Kryczka WM, Skiba E. Adv Med Sci. 2010 Apr 6:1-7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20371429

 

Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country. Davíđsdóttir L, Duberg AS, Törner A, et al. Scand J Gastroenterol. 2010 Apr 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20384529

 

Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study. Padua MA, Fonseca AM, Deguti MM, et al. Climacteric. 2010 Apr;13(2):179-86.

http://www.ncbi.nlm.nih.gov/pubmed/19657792

 

Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. Olmez OF, Gurel S, Yilmaz Y. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):461-5.

http://www.ncbi.nlm.nih.gov/pubmed/19940783

 

Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. Zekri AR, Moharram RA, Mohamed WS, et al. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):450-6.

http://www.ncbi.nlm.nih.gov/pubmed/19858727

 

Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C Trial. Seeff LB, Everson GT, Morgan TR, et al. Clin Gastro-enterol Hepatol. 2010 Apr 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20362695

 

High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. Waizmann M, Ackermann G. J Subst Abuse Treat. 2010 Jun;38(4):338-45. Epub 2010 Apr 1.

http://www.ncbi.nlm.nih.gov/pubmed/20362408

 

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Petta S, Cammŕ C, Scazzone C, et al. Hepatology. 2010 Apr;51(4):1158-67.

http://www.ncbi.nlm.nih.gov/pubmed/20162613

 

Hepatobiliary function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of fibrosis in chronic hepatitis: histopathological correlation. Kula M, Karacavus S, Baskol M, et al. Nucl Med Commun. 2010 Apr;31(4):280-5.

http://www.ncbi.nlm.nih.gov/pubmed/20087241

 

Outcome of a hepatitis C outbreak among patients in a pain management clinic. Fazili J, Mallonee S, Tierney WM, et al. Dig Dis Sci. 2010 Apr 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20411419

 

Basic and Applied Science, Pre-Clinical Studies

 

Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Talaat RM. Viral Immunol. 2010 Apr;23(2):151-7.

http://www.ncbi.nlm.nih.gov/pubmed/20373995

 

Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity.

Wang S, Buchli R, Schiller J, et al. World J Gastroenterol. 2010 Apr 28;16(16):1953-69.

http://www.ncbi.nlm.nih.gov/pubmed/20419832

 

Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Knapp S, Warshow U, Hegazy D, et al. Hepatology. 2010 Apr;51(4):1168-75.

http://www.ncbi.nlm.nih.gov/pubmed/20077564

 

Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles. Velázquez F, Sannigrahi M, Bennett F, et al. J Med Chem. 2010 Apr 22;53(8):3075-85.

http://www.ncbi.nlm.nih.gov/pubmed/20302300

 

The protease domain increases the translocation stepping efficiency of the hepatitis C virus NS3-4A helicase. Rajagopal V, Gurjar M, Levin MK, Patel SS. J Biol Chem. 2010 Apr 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20363755

 

A small molecule inhibits HCV replication and alters NS4B's subcellular distribution.

Bryson PD, Cho NJ, Einav S, et al. Antiviral Res. 2010 Apr 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20363257

 

Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system.

Bellecave P, Sarasin-Filipowicz M, et al. Hepatology. 2010 Apr;51(4):1127-36.

http://www.ncbi.nlm.nih.gov/pubmed/20044805

 

Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Langhans B, Braunschweiger I, Arndt S, et al. Clin Sci (Lond). 2010 Apr 20;119(2):97-109.

http://www.ncbi.nlm.nih.gov/pubmed/20222873

 

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Akuta N, Suzuki F, Hirakawa M, et al. J Med Virol. 2010 Apr;82(4):575-82.

http://www.ncbi.nlm.nih.gov/pubmed/20166188

 

CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Zaldivar MM, Pauels K, von Hundelshausen P, et al.

http://www.ncbi.nlm.nih.gov/pubmed/20162727

 

Positive selection of core 70Q variant genotype 1b hepatitis c virus strains induced by pegylated interferon and ribavirin. Kurbanov F, Tanaka Y, Matsuura K, et al. J Infect Dis. 2010 Apr 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20420509

 

 

 

 

HIV/HCV Coinfection

 

Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells. Page EE, Cox A, Atkins M, Nelson MR. AIDS. 2010 Apr 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20386424

 

Hepatitis C virus RNA detection in different semen fractions of HCV/HIV-1 co-infected men by nested PCR. Savasi V, Parrilla B, Ratti M, Oneta M, Clerici M, Ferrazzi E. Eur J Obstet Gynecol Reprod Biol. 2010 Apr 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20382466

 

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. Van den Eynde E, Tiraboschi JM, Tural C, et al. AIDS. 2010 Apr 24;24(7):975-82.

http://www.ncbi.nlm.nih.gov/pubmed/20299963

 

Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Seminari E, Tinelli C, Ravasi G, et al. Curr HIV Res. 2010 Apr 1;8(3):186-93.

http://www.ncbi.nlm.nih.gov/pubmed/20163342

 

Is statin therapy safe in patients with HIV/hepatitis C coinfection? Stroup JS, Harris B. Proc (Bayl Univ Med Cent). 2010 Apr;23(2):111-3.

http://www.ncbi.nlm.nih.gov/pubmed/20396416

 

Complementary and Alternative Medicine

 

A novel approach to evaluate traditional Chinese medicine treatment outcomes using pattern identification. Berle CA, Cobbin D, Smith N, Zaslawski C. J Altern Complement Med. 2010 Apr;16(4):357-67.

http://www.ncbi.nlm.nih.gov/pubmed/20374102

 

Aminofeel improves the sensitivity to taste in patients with HCV-infected liver disease.

Nagao Y, Matsuoka H, Kawaguchi T, Sata M. Med Sci Monit. 2010 Apr 1;16(4):PI7-12.

http://www.ncbi.nlm.nih.gov/pubmed/20357731

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Treatment of HBV/HCV coinfection. Potthoff A, Manns MP, Wedemeyer H. Expert Opin Pharmacother. 2010 Apr;11(6):919-28.

http://www.ncbi.nlm.nih.gov/pubmed/20166841

 

 

Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. J Med Virol. 2010 Apr;82(4):546-55.

http://www.ncbi.nlm.nih.gov/pubmed/20166185

 

Analysis of hepatitis C virus strains circulating in Republic of the Congo. Cantaloube JF, Gallian P, Bokilo A, et al. J Med Virol. 2010 Apr;82(4):562-7.

http://www.ncbi.nlm.nih.gov/pubmed/20166180

 

Hepatitis C virus infection in a Japanese leprosy sanatorium for the past 67 years.

Shiogama K, Teramoto H, Morita Y, et al. J Med Virol. 2010 Apr;82(4):556-61.

http://www.ncbi.nlm.nih.gov/pubmed/20166169

 

Performance evaluation of the Abbott RealTime HCV Genotype II for hepatitis C virus genotyping. Sohn YH, Ko SY, Kim MH, Oh HB. Clin Chem Lab Med. 2010 Apr;48(4):469-74.

http://www.ncbi.nlm.nih.gov/pubmed/20128734

 

Identification of substance use and dependence among patients with viral hepatitis.

Jackson CB, Varon J, Ho A, et al. Dig Liver Dis. 2010 Apr 23. [Epub ahead of print]

Marks KM, Talal AH, Kreek MJ.

http://www.ncbi.nlm.nih.gov/pubmed/20418192

 

Comorbidities associated with the increasing burden of hepatitis C infection. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Liver Int. 2010 Apr 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20408945

 

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. Ogawa E, Furusyo N, Toyoda K, et al. BMC Gastroenterol. 2010 Apr 16;10(1):38. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20398383

 

Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Psychiatry Res. 2010 May 15;177(1-2):240-245. Epub 2010 Apr 9.

http://www.ncbi.nlm.nih.gov/pubmed/20381876

 

Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. J Clin Gastroenterol. 2010 Apr;44(4):e87-95.

http://www.ncbi.nlm.nih.gov/pubmed/19881359

 

Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection.

Lee SR, Yearwood GD, Guillon GB, et al. Clin Virol. 2010 May;48(1):15-7. Epub 2010 Apr 1.

http://www.ncbi.nlm.nih.gov/pubmed/20362493

 

 

Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Anastasiou J, Alisa A, Virtue S, et al. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):474-80.

http://www.ncbi.nlm.nih.gov/pubmed/19887952